Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1218220090010020081
Korean Journal of Pediatric Urology
2009 Volume.1 No. 2 p.81 ~ p.86
Endoscopic Injection Therapy in Vesicoureteral Reflux: Review of Long-term Followup Data
Kim Kun-Suk

Abstract
Vesicoureteral reflux (VUR) is a common disease and is present in 25-40% of children with urinary tract infection. The primary aim of reflux therapy is to prevent pyelonephritis, renal scarring, hypertension and chronic renal failure. This therapy can be either medical or surgical. In recent years, the management of VUR has changed dramatically, mostly because of the widespread acceptance of endoscopic treatment. Since the first clinical application in 1984 as subureteric Teflon injection, injection techniques, injectable agents and consequently treatment success rates have considerably improved. Endoscopic injection, particularly when dextranomer hyaluronic acid (DxHA) is used, has become increasingly popular in many parts of the world. DxHA has been shown to be well tolerated and to have long-term efficacy in the endoscopic treatment of VUR. Furthermore this technique with DxHA has proven to be effective in complex cases that were previously considered as contraindications for endoscopic treatment, including high-grade VUR, voiding dysfunction, duplex ureters and paraureteral diverticulum. The development of new injectable agents in combination with the improvement of endoscopic techniques will continue to strengthen the role of endoscopic treatment for VUR.
KEYWORD
Vesicoureteral reflux, Endoscopic treatment, Dextranomer hyaluronic acid
FullTexts / Linksout information
Listed journal information